Addressing Treatment Gaps in HER2+ MBC
Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.
Optimizing Therapy in HER2+ MBC Across the Globe
A global perspective on managing patients with HER2-positive metastatic breast cancer through multiple lines of therapy based on treatment advances.
Therapeutic Sequencing in HER2+ MBC
A global perspective pertaining to how to best sequence therapies used to treat HER2+ metastatic breast cancer based on treatment advances and data presented on at ESMO 2021.
Updates to HER2CLIMB in HER2+ MBC
Breast oncologists react to updated overall survival data, progression-free survival data, and quality-of-life data from the HER2CLIMB study of tucatinib for HER2+ metastatic breast cancer, as well as consider using the drug in combination with other novel therapies.
Managing TRAEs Associated With Novel HER2+ MBC Therapies
Recommendations for monitoring for and managing adverse events associated with newer therapies being sequenced into HER2+ metastatic breast cancer treatment algorithms.
Updated Data From DESTINY-Breast03 in HER2+ MBC
Practice-changing data from the DESTINY-Breast03 trial evaluating trastuzumab deruxtecan as second-line therapy in HER2-positive metastatic breast cancer presented at ESMO 2021.
Standard Treatment Approaches in HER2+ MBC
A global perspective regarding standards of care for treating HER2-positive metastatic breast cancer in earlier treatment settings.
Global Trends in HER2+ MBC
Breast oncologists from across the globe react to incidence rates of HER2-positive metastatic breast cancer as they relate to rates of progression to brain metastases and treatment advances.
Rapid Readout: Assessment of Tucatinib vs Placebo in the HER2CLIMB Study of Pretreated Patients with HER2+ Metastatic Breast Cancer
Expert oncologist Giuseppe Curigliano, MD, PhD, reflects on the updated results of the HER2CLIMB study evaluating tucatinib against placebo, each in combination with trastuzumab and capecitabine, in patients with pretreated HER2+ metastatic breast cancer.
Future Opportunities With Novel Therapies for HER2+ Breast Cancer
Novel therapies that show promise in addressing treatment gaps in HER2-positive breast cancer, and exciting data that are expected to be reported on at the upcoming ESMO 2021 meeting.
R/R Metastatic HER2+ Breast Cancer Treatment Considerations
Factors that impact treatment selection for patients with metastatic HER2-positive breast cancer who progress on HER2-targeted therapy.
HER2+ Breast Cancer: Key Takeaways From HER2CLIMB
An overview of the latest data demonstrated by the HER2CLIMB study evaluating the efficacy and safety of tucatinib in combination with capecitabine and trastuzumab for patients with relapsed/refractory metastatic HER2-positive breast cancer.
Standard of Care for R/R Metastatic HER2+ Breast Cancer
Current treatment options and outcomes for patients with metastatic HER2-positive breast cancer who progress on HER2-targeted therapy, with special insight regarding the management of brain metastasis and visceral disease.
Dr. Curigliano Discusses Immunotherapy Trials in Breast Cancer
Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses immunotherapy trials in triple-negative breast cancer.
Dr. Curigliano Discusses Immunotherapy in Breast Cancer
Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses the emergence of immunotherapy in breast cancer.
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
2 Commerce Drive Cranbury, NJ 08512